Drug Makers Agree to Develop Experimental Prostate Cancer Drug

by: cancercompass

Astellas Pharma Inc. of Japan will pay San Francisco-based drug maker Medivation $110 million as part of global agreement to develop and market the experimental prostate cancer drug MDV3100, reports the San Francisco Chronicle.

Medivation announced in September that patient enrollment began for the Phase 3 clinical trial for MDV3100. Called AFFIRM, the goal of the trial is to evaluate how MDV3100, an androgen receptor antagonist drug, works in men with castration-resistant prostate cancer who were previously treated with docetaxel-based chemotherapy.

In the Phase 1-2 clinical trial, MDV3100 reportedly reduced by 50% a biomarker of prostate cancer in 43% of the first 30 patients treated. Results of this trial were published in the May edition of Science. A synopsis is available at PubMed.gov.

Share your thoughts about new drug therapies at our Prostate Cancer Message Board.